Display options
Cite
Griffiths PD, Mahungu T. Why CMV is a candidate for elimination and then eradication. J Virus Erad. 2016;2(3):131-5
Griffiths, P. D., & Mahungu, T. (2016). Why CMV is a candidate for elimination and then eradication. Journal of virus eradication, 2(3), 131-5.
Griffiths, Paul D, and Mahungu, Tabitha. "Why CMV is a candidate for elimination and then eradication." Journal of virus eradication vol. 2,3 (2016): 131-5.
Griffiths PD, Mahungu T. Why CMV is a candidate for elimination and then eradication. J Virus Erad. 2016 Jul 01;2(3):131-5. PMID: 27482451; PMCID: PMC4967963.
Copy Download .nbib Format: NLM
Share it on

J Virus Erad. 2016 Jul 01;2(3):131-5.

Why CMV is a candidate for elimination and then eradication.

Journal of virus eradication

Paul D Griffiths, Tabitha Mahungu

Affiliations

  1. Centre for Virology , University College London Medical School , UK.

PMID: 27482451 PMCID: PMC4967963

Abstract

Cytomegalovirus (CMV) is well-known for the end organ diseases (EODs) it causes following viraemic dissemination in immunocompromised hosts. These are termed the direct effects of CMV, where a diagnosis can be made in an individual patient. In addition, CMV is associated with indirect effects where populations can be seen to be disadvantaged compared to those without CMV. These indirect effects have been described in solid organ transplants, bone marrow transplants, advanced HIV, people admitted to intensive care units, the elderly and the general population. We summarise the evidence that associates CMV with its direct effects following congenital infection, solid organ transplantation, bone marrow transplantation and advanced HIV as well as its indirect effects in all patient populations. We propose that the greatest worldwide burden of CMV comes from its indirect effects. Control of this infection at the population level is being sought through the development of vaccines to control EODs where cost effectiveness is expected. We propose that the financial case for universal immunisation will be enhanced even further by the potential benefits vaccines may produce against the indirect effects of CMV.

Keywords: CMV; cytomegalovirus; immunocompromise; indirect effects; vaccine

References

  1. Lancet. 1989 Sep 16;2(8664):681 - PubMed
  2. J Virol. 1999 Aug;73(8):7027-30 - PubMed
  3. J Infect Dis. 1997 May;175(5):1080-6 - PubMed
  4. N Engl J Med. 2015 Mar 5;372(10):933-43 - PubMed
  5. Lancet Infect Dis. 2011 Apr;11(4):284-92 - PubMed
  6. Am J Transplant. 2012 Sep;12(9):2457-64 - PubMed
  7. Clin Immunol. 1999 Feb;90(2):213-9 - PubMed
  8. J Infect Dis. 2011 May 15;203(10):1474-83 - PubMed
  9. Lancet Infect Dis. 2012 Oct;12(10):790-8 - PubMed
  10. J Infect Dis. 2015 Jan 15;211(2):178-86 - PubMed
  11. Proc Soc Exp Biol Med. 1957 Jan;94(1):4-12 - PubMed
  12. N Engl J Med. 2013 Sep 26;369(13):1227-36 - PubMed
  13. Lancet. 2004 Jun 26;363(9427):2116-21 - PubMed
  14. PLoS One. 2011 Feb 17;6(2):e16103 - PubMed
  15. J Infect Dis. 2008 Mar 15;197(6):836-45 - PubMed
  16. AIDS. 1997 Jun;11(7):889-93 - PubMed
  17. Blood. 2008 Jun 1;111(11):5403-10 - PubMed
  18. J Infect Dis. 1997 Dec;176(6):1484-90 - PubMed
  19. J Exp Med. 1999 Jul 19;190(2):177-82 - PubMed
  20. Transplantation. 2013 Aug 27;96(4):333-60 - PubMed
  21. Infect Agents Dis. 1992 Oct;1(5):237-44 - PubMed
  22. Rev Med Virol. 2009 Jan;19(1):47-56 - PubMed
  23. Blood. 2009 Jun 4;113(23):5711-9 - PubMed
  24. Curr Opin Virol. 2011 Dec;1(6):555-62 - PubMed
  25. N Engl J Med. 1964 Nov 12;271:1021-7 - PubMed
  26. J Pediatr. 2003 Jul;143(1):16-25 - PubMed
  27. N Engl J Med. 2002 Apr 11;346(15):1119-26 - PubMed
  28. J Clin Virol. 2009 Dec;46 Suppl 4:S22-6 - PubMed
  29. N Engl J Med. 1982 Apr 22;306(16):945-9 - PubMed
  30. J Infect Dis. 2000 May;181(5):1800-3 - PubMed
  31. Bone Marrow Transplant. 1998 Mar;21(6):597-605 - PubMed
  32. Am J Pathol. 1925 Sep;1(5):445-466.3 - PubMed
  33. Blood. 2004 Mar 15;103(6):2003-8 - PubMed
  34. Lancet. 1994 Mar 26;343(8900):749-53 - PubMed
  35. N Engl J Med. 2014 May 8;370(19):1781-9 - PubMed
  36. N Engl J Med. 1996 Jun 6;334(23):1491-7 - PubMed
  37. Am J Transplant. 2004 Apr;4(4):611-20 - PubMed
  38. Lancet. 2000 Jun 10;355(9220):2032-6 - PubMed
  39. Transpl Infect Dis. 1999;1 Suppl 1:25-30 - PubMed
  40. Clin Infect Dis. 2013 May;56(10):1421-7 - PubMed
  41. JAMA. 1989 Jun 23-30;261(24):3561-6 - PubMed
  42. JAMA. 1989 Jun 23-30;261(24):3607-9 - PubMed
  43. J Med Virol. 2013 Sep;85(9):1557-60 - PubMed
  44. J Infect Dis. 1975 Nov;132(5):568-77 - PubMed
  45. N Engl J Med. 1999 May 13;340(19):1462-70 - PubMed
  46. Am J Transplant. 2010 May;10(5):1228-37 - PubMed

Publication Types